Smart Relief Alliance 360: Unlocking Public-Private Synergy for Global Health & Wealth Creation
BioElectronics Corporation (BIEL) isn't just expanding—it's strategically activating its public company status to propel worldwide growth, strengthen institutional credibility, and deliver financial upside to its core partners: Viant Medical and VLMS Global Healthcare.
Global ActiPatch Momentum: Market Validation & Partner ROI
BIEL’s flagship device, ActiPatch, is making international waves—proving efficacy while unlocking new revenue streams:
Taiwan: 14 top-tier hospitals, including NTU Hospital, are now deploying ActiPatch—fueling VLMS’s billing platforms and Viant’s production scale.
South Africa: Adcock Ingram’s dual retail/clinical distribution bolsters brand trust and boosts manufacturing and backend analytics.
New Zealand: DTC rollout delivers rich consumer insights and drives scalable fulfillment volumes.
Public Status = Private Partner Acceleration
BIEL’s position on public markets offers distinct advantages for private partners:
Capital for Growth Public fundraising fuels Viant’s hardware scale-up and VLMS’s global reimbursement infrastructure.
Institutional Trust Transparency from public trading opens access to hospital systems and retailers that demand reliability and legitimacy.
Shared Market Lift
VLMS monetizes coding, billing & analytics
Viant fulfills hardware and software demand
BIEL captures top-line growth for shareholder value
Strategic Equity = Wealth Creation for Partners
Private partners evolve from contributors to co-owners through equity accumulation:
Profit Through Ownership VLMS and Viant can acquire BIEL shares—translating execution into portfolio appreciation.
No Dilution, All Upside Partners stay private while accessing public liquidity and equity growth.
Governance Leverage Equity stakes allow direct influence on commercialization, innovation pipeline, and investor strategy.
Unified Mission, Aligned Incentives Ownership builds trust, accountability, and long-term decision alignment across stakeholders.
Legislative Catalyst: NOPAIN for Veterans Act + FDA-Cleared Solutions
Game-changing opportunity emerges with bipartisan legislation that supports BIEL’s mission:
VA Access & Reimbursement The Act mandates VA coverage for non-opioid pain therapies already approved by Medicare—making ActiPatch and RecoveryRx eligible for formulary inclusion, direct reimbursement, and VA prescribing.
VLMS & Viant Advantage
VLMS leads claims integration via AI-powered RCM
Viant scales FDA-compliant production for VA orders
BIEL PPS Growth Opportunity Increased revenue, institutional adoption, and investor confidence fuel stock performance.
Mission Alignment BIEL positions itself as a public force in opioid-free pain relief—serving millions of veterans through safe, scalable solutions.
Build the Ecosystem. Own the Future.
Viant: Builds hardware
VLMS: Powers reimbursement
BIEL: Scales markets, raises capital, grows shareholder value
Together, they’re delivering a smart, reimbursable, AI-enhanced pain management platform—right when policy support, clinical validation, and global demand align for breakout impact.
BioElectronics Corporation (BIEL) isn't just expanding—it's strategically activating its public company status to propel worldwide growth, strengthen institutional credibility, and deliver financial upside to its core partners: Viant Medical and VLMS Global Healthcare.
Global ActiPatch Momentum: Market Validation & Partner ROI
BIEL’s flagship device, ActiPatch, is making international waves—proving efficacy while unlocking new revenue streams:
Taiwan: 14 top-tier hospitals, including NTU Hospital, are now deploying ActiPatch—fueling VLMS’s billing platforms and Viant’s production scale.
South Africa: Adcock Ingram’s dual retail/clinical distribution bolsters brand trust and boosts manufacturing and backend analytics.
New Zealand: DTC rollout delivers rich consumer insights and drives scalable fulfillment volumes.
Public Status = Private Partner Acceleration
BIEL’s position on public markets offers distinct advantages for private partners:
Capital for Growth Public fundraising fuels Viant’s hardware scale-up and VLMS’s global reimbursement infrastructure.
Institutional Trust Transparency from public trading opens access to hospital systems and retailers that demand reliability and legitimacy.
Shared Market Lift
VLMS monetizes coding, billing & analytics
Viant fulfills hardware and software demand
BIEL captures top-line growth for shareholder value
Strategic Equity = Wealth Creation for Partners
Private partners evolve from contributors to co-owners through equity accumulation:
Profit Through Ownership VLMS and Viant can acquire BIEL shares—translating execution into portfolio appreciation.
No Dilution, All Upside Partners stay private while accessing public liquidity and equity growth.
Governance Leverage Equity stakes allow direct influence on commercialization, innovation pipeline, and investor strategy.
Unified Mission, Aligned Incentives Ownership builds trust, accountability, and long-term decision alignment across stakeholders.
Legislative Catalyst: NOPAIN for Veterans Act + FDA-Cleared Solutions
Game-changing opportunity emerges with bipartisan legislation that supports BIEL’s mission:
VA Access & Reimbursement The Act mandates VA coverage for non-opioid pain therapies already approved by Medicare—making ActiPatch and RecoveryRx eligible for formulary inclusion, direct reimbursement, and VA prescribing.
VLMS & Viant Advantage
VLMS leads claims integration via AI-powered RCM
Viant scales FDA-compliant production for VA orders
BIEL PPS Growth Opportunity Increased revenue, institutional adoption, and investor confidence fuel stock performance.
Mission Alignment BIEL positions itself as a public force in opioid-free pain relief—serving millions of veterans through safe, scalable solutions.
Build the Ecosystem. Own the Future.
Viant: Builds hardware
VLMS: Powers reimbursement
BIEL: Scales markets, raises capital, grows shareholder value
Together, they’re delivering a smart, reimbursable, AI-enhanced pain management platform—right when policy support, clinical validation, and global demand align for breakout impact.
